The price of Protalix BioTherapeutics Inc (AMEX:PLX) shares last traded on Wall Street rose 2.67% to $1.54.
PLX stock price is now -18.02% away from the 50-day moving average and -18.32% away from the 200-day moving average. The market capitalization of the company currently stands at $122.59M.
With the price target enhanced from $3 to $11, H.C. Wainwright maintained Buy rating for Protalix BioTherapeutics Inc (AMEX: PLX). On April 17, 2017, Rodman & Renshaw reiterated its ‘Buy’ rating on the stock by increasing its target price from $4 to quote $5, while ‘Jefferies’ rates the stock as ‘Buy’
A total of 7.28% of the company’s stock is owned by insiders.
During the past 12 months, Protalix BioTherapeutics Inc has had a low of $0.82 and a high of $3.10. As of last week, the company has a debt-to-equity ratio of 0.12, a current ratio of 2.49, and a quick ratio of 1.69. The fifty day moving average price for PLX is $1.8786 and a two-hundred day moving average price translates $1.8855 for the stock.
The latest earnings results from Protalix BioTherapeutics Inc (AMEX: PLX) was released for 2025-03-31. The net profit margin was 6.54% and return on equity was 10.42% for PLX. The company reported revenue of $10.11 million for the quarter, compared to $3.75 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 169.82 percent.
